Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026

Annexon, Inc.

2024-Q2 EPS reported -$0.43

Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.
Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.
ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.
ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.
ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.